Profile data is unavailable for this security.
About the company
Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
- Revenue in CHF (TTM)6.03m
- Net income in CHF-17.31m
- Incorporated2002
- Employees23.00
- LocationNewron Pharmaceuticals SpAvia Ludovico Ariosto 21BRESSO 20091ItalyITA
- Phone+39 26103461
- Fax+39 261034654
- Websitehttps://www.newron.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kuros Biosciences AG | 17.99m | -14.60m | 46.62m | 64.00 | -- | 0.6766 | -- | 2.59 | -0.429 | -0.429 | 0.5306 | 1.88 | 0.2064 | 2.93 | 7.98 | -- | -16.75 | -12.75 | -19.41 | -13.72 | 59.87 | 73.64 | -81.15 | -144.70 | 2.24 | -5.28 | 0.027 | -- | 30.19 | 102.06 | -93.54 | -- | -23.96 | -- |
| Santhera Pharmaceuticals Holding AG | 163.00k | -64.73m | 78.37m | 39.00 | -- | -- | -- | 480.78 | -1.28 | -1.28 | 0.0032 | -0.2553 | 0.002 | 11.11 | 0.087 | 4,179.49 | -80.91 | -48.15 | -168.64 | -60.86 | -2,115.34 | 80.16 | -39,712.27 | -172.87 | 0.372 | -82.93 | 1.52 | -- | -110.63 | -- | 17.93 | -- | -47.47 | -- |
| Wockhardt Bio AG | 304.59m | -41.29m | 83.43m | -- | -- | 0.2909 | -- | 0.2739 | -0.7398 | -0.7398 | 5.86 | 5.52 | 0.4792 | 1.80 | 2.50 | -- | -6.50 | -0.7439 | -8.19 | -1.25 | 51.44 | 52.97 | -13.55 | -1.62 | 3.90 | -3.45 | 0.5092 | -- | 12.15 | -2.14 | -107.96 | -- | -8.03 | -- |
| Evolva Holding SA | 15.54m | -43.37m | 84.41m | 50.00 | -- | 0.7885 | -- | 5.43 | -0.0423 | -0.0423 | 0.0145 | 0.0951 | 0.1082 | 1.08 | 3.64 | 310,788.00 | -30.20 | -18.10 | -34.24 | -19.67 | -20.17 | -13.60 | -279.07 | -309.14 | 0.6288 | -6.43 | 0.1241 | -- | 57.32 | 17.81 | -5.09 | -- | -3.57 | -- |
| RELIEF THERAPEUTICS Holding SA | 7.87m | -46.53m | 107.27m | 55.00 | -- | 0.4961 | -- | 13.64 | -0.0116 | -0.0116 | 0.002 | 0.0385 | 0.0392 | 6.09 | 4.64 | 143,018.20 | -23.16 | -17.42 | -25.24 | -18.92 | 81.96 | -- | -591.50 | -1,372.00 | 2.78 | -51.30 | 0.0247 | -- | -- | 194.47 | -343.34 | -- | 316.02 | -- |
| Newron Pharmaceuticals SpA | 6.03m | -17.31m | 110.34m | 23.00 | -- | -- | -- | 18.29 | -0.9702 | -0.9702 | 0.338 | -0.7781 | 0.139 | -- | 3.75 | 262,234.10 | -39.90 | -31.99 | -44.29 | -35.22 | 92.73 | 87.04 | -287.05 | -314.56 | -- | -2.91 | 1.44 | -- | 5.76 | -14.43 | -17.39 | -- | -21.91 | -- |
| Xlife Sciences AG | 863.90k | 48.92m | 174.36m | 19.00 | 5.91 | 0.8287 | 3.23 | 201.83 | 5.59 | 5.59 | 0.1309 | 39.82 | 0.0026 | -- | 2.32 | 45,468.42 | 13.92 | -- | 16.67 | -- | 38.79 | -- | 5,327.34 | -- | -- | -0.6138 | 0.1615 | -- | 103.14 | -- | 148.91 | -- | -- | -- |
| Molecular Partners AG | 189.60m | 117.85m | 197.23m | 175.00 | 1.55 | 0.757 | 1.64 | 1.04 | 3.53 | 3.53 | 5.77 | 7.23 | 0.8719 | -- | 14.22 | 1,083,429.00 | 54.19 | -9.96 | 63.57 | -12.86 | -- | 98.42 | 62.16 | -34.26 | -- | -- | 0.0202 | -- | 1,843.82 | 56.78 | 284.77 | -- | 23.16 | -- |
Data as of Mar 27 2023. Currency figures normalised to Newron Pharmaceuticals SpA's reporting currency: Swiss Franc CHF
3.71%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Credit Suisse Asset Management (Schweiz) AGas of 28 Feb 2023 | 207.95k | 1.17% |
| Z�rcher Kantonalbank (Investment Management)as of 31 Dec 2020 | 173.17k | 0.97% |
| UBS Asset Management Switzerland AGas of 28 Feb 2023 | 146.25k | 0.82% |
| TOBAM SASas of 31 Dec 2020 | 51.25k | 0.29% |
| Pictet Asset Management SAas of 30 Nov 2022 | 29.73k | 0.17% |
| BlackRock Asset Management Schweiz AGas of 01 Mar 2023 | 25.02k | 0.14% |
| Lombard Odier Asset Management (Switzerland) SAas of 30 Dec 2022 | 15.24k | 0.09% |
| DWS CH AGas of 31 Jan 2023 | 6.25k | 0.04% |
| LLB Asset Management AGas of 31 Dec 2022 | 3.65k | 0.02% |
| Migros Bank AGas of 30 Jun 2021 | 3.62k | 0.02% |
More ▼
Data from 31 Dec 2021 - 31 Jan 2023Source: FactSet Research Systems Inc.
